HPV and Head & Neck Cancer: A New Risk Factor and a New Patient Profile

Head & neck cancer was historically linked to smoking and alcohol — older men with long smoking histories were the patient profile. The last 20 years have seen a dramatic shift: HPV-positive oropharyngeal cancer (tonsils and base of tongue) has rapidly risen, especially in developed countries. In the US and Western Europe today, 70-80% of new head & neck cancer cases are HPV-positive. In Türkiye the rate is lower (~30-40%) but rising rapidly.

Cause: shifts in sexual behaviour. Oral sex has become more common (clear rise across society since the 1980s); HPV transmission from genital to oral mucosa increased. HPV is known as the "cervical cancer virus"; the same virus causes cancer in oral and throat mucosa.

This redefines head & neck cancer epidemiology. The classical profile — smoking, alcohol, 60+, M:F 4:1 — still exists, but a new profile has joined it: HPV-positive, 40-60, non-smoker, light drinker, oral sex history, male (4:1 vs female). Two different diseases under one name. Related overview: our head and neck cancer surgery programme.

HPV is a DNA virus with 200+ types. Most are "low risk" (cause warts, not cancer); 14 types are "high risk" (HPV-16, 18, 31, 33, 45, 52, 58 etc.). Type 16 causes 85-90% of HPV-positive head & neck cancers. Type 18 is less but still important.

Transmission: 1) Oral sex (the main route) — a partner's genital HPV is carried to oral mucosa. 2) Sexual intercourse — vaginal/anal infections sometimes reach the oral flora. 3) Mother-to-baby at delivery (rare — childhood laryngeal papillomatosis). 4) Skin contact for some types (not the oropharyngeal-cancer types).

HPV infection is not cancer. 80% of sexually active people will have at least one HPV infection; in 90% the immune system clears it in 1-2 years. Only 5-10% have persistent infection long enough (10-20 years) for cancer development.

Who is at risk: men with many sexual partners (especially 6+ oral sex partners), partners of those with cervical cancer, immunocompromised (HIV, transplant, immunosuppressive therapy), smokers (smoking impairs HPV clearance, prolonging persistent infection).

The classical sign of HPV-positive oropharyngeal cancer: a one-sided enlarging painless neck mass. This is the first sign in most cases (70%). The patient usually does not notice the primary tumour (tonsil or base of tongue) because it does not cause pain, bleeding, or swallowing difficulty early on.

This is the root of the "late diagnosis problem". The patient ignores the neck lump for 1-2 months ("must be a swollen gland"), then sees a family doctor, who tries antibiotics (thinking lymph node infection); after 2-4 weeks of no shrinkage, referral to ENT. Total: 2-3 months — delayed diagnosis.

Other signs (more advanced): 1) Sore throat (one-sided, persistent), 2) Pain on swallowing (odynophagia), 3) One-sided ear pain (referred pain — from tonsillar tumour), 4) Throat fullness, 5) Voice change (hoarseness usually late), 6) Weight loss, 7) Trismus (difficulty opening mouth — tumour extending to chewing muscles).

Diagnosis: ENT exam + nasal endoscopy (posterior tonsil, base of tongue); biopsy of suspicious lesion + neck ultrasound/CT, and HPV testing (p16 immunohistochemistry and/or HPV-DNA testing). HPV status is critical for treatment selection and prognosis.

The most striking feature of HPV-positive cancer: prognosis is dramatically better than HPV-negative. At the same stage, HPV-positive 5-year survival is 80-90%; HPV-negative 50-60%. A landmark observation in head & neck oncology.

Reason: HPV-positive tumours are genetically "cleaner" — fewer additional mutations, so they respond better to treatments. Radiotherapy is especially effective; in some cases radiotherapy alone (without surgery) suffices. Chemotherapy also has good effect.

For this reason the American Joint Committee on Cancer (AJCC) changed the head & neck staging system in 2017: HPV-positive cases use a different stage table. The same tumour size is lower stage with better prognosis in HPV-positive disease.

Treatment options are more "flexible" for HPV-positive: 1) Surgery + radiotherapy (classic), 2) Radiotherapy + chemotherapy (organ-sparing), 3) Radiotherapy alone (selected early cases). 4) "De-escalation" trials — less intense treatment with the same outcome. This greatly improves quality of life (speech, swallowing, nutrition preserved). Step-by-step details: oropharyngeal cancer details.

The HPV vaccine (Gardasil 9) is the most powerful tool for head & neck cancer prevention. It covers 9 high-risk HPV types (16, 18, 31, 33, 45, 52, 58 + 6 and 11 low-risk for warts). The vaccine produces antibodies that block viral entry to cells.

When to vaccinate: ideally 9-13 — before sexual activity (no HPV exposure yet). At this age 2 doses suffice. From 14 to 26 — 3 doses; even with active sexual activity the vaccine still protects against types not yet encountered.

Should men also be vaccinated? Yes! In Türkiye the vaccine was originally recommended only for girls (cervical cancer) but HPV-positive head & neck cancer is more common in men, so boys are now standard. WHO, US CDC and Türkiye Ministry of Health recommend regardless of sex.

Adult vaccination: 27-45 in selected individuals (especially those with a new sexual partner, high-risk group). But adult vaccination is less effective than childhood vaccination.

Screening: routine screening like Pap for cervical cancer does not yet exist for HPV head & neck cancer. Research methods: oral HPV-DNA test (saliva), blood test (circulating HPV-DNA). Not yet approved for clinical use.

In Türkiye, HPV-positive head & neck cancer rate (~30-40%) is lower than Western countries but rising rapidly. Reasons: 1) Shifting sexual behaviour (younger generation imitating Western patterns), 2) Relatively low vaccination coverage (Türkiye added the vaccine to its national programme in 2022; not yet widespread), 3) Smoking rates still high (classical head & neck cancer profile persists — both factors rising in parallel).

HPV testing in Türkiye: p16 immunohistochemistry is available in all major-city pathology labs. HPV-DNA testing (PCR) is in selected centres. Affordable, results in 1-2 weeks.

For international patients: head & neck cancer treatment in Türkiye meets high standards. Academic university hospitals (Cerrahpaşa, Istanbul Faculty of Medicine, Hacettepe, Marmara) and JCI-accredited private hospitals (Acıbadem, Memorial, Florence Nightingale) treat HPV-positive cases with modern protocols.

Treatment cost in Türkiye is 50-70% lower than Western countries — driving international oncology patient flow. Some international patients come to Türkiye because wait times in their country are long (NHS, Germany, Italy) or cost is very high (US).

After HPV-positive head & neck cancer treatment, quality of life is generally better than after HPV-negative. Reason: tumours respond well to organ-sparing therapy (when surgery is not needed, speech, swallowing, nutrition are preserved), and early-stage detection is more likely.

Post-treatment period: first year close follow-up (3-monthly exam + imaging), then 6-monthly for years 2-5, then annual. Recurrence risk is highest in the first 2-3 years and declines.

Speech and swallowing rehabilitation: speech therapist and nutritionist provide important support. These should be standard during and after treatment. Major Turkish university hospitals and oncology centres include these.

Psychological support: a cancer diagnosis is traumatic; with HPV-positive cancer there can be additional guilt about "sexually transmitted virus". Psychological/psychiatric support matters — carrying HPV is not blameworthy, it's biology; most sexually active people are exposed to HPV.

Partner risk: is the patient's partner at additional risk? No direct risk (HPV transmission is from before; if partner is unvaccinated and has active HPV infection, additional screening can be considered). Practically: cervical cancer screening (for female partners) continues if already in place. Related reading: our multidisciplinary tumour board.